about
Caffeine augments the antidepressant-like activity of mianserin and agomelatine in forced swim and tail suspension tests in mice.Magnesium in depression.Caffeine enhances the antidepressant-like activity of common antidepressant drugs in the forced swim test in miceMagnesium and depression.Influence of the selective antagonist of the NR2B subunit of the NMDA receptor, traxoprodil, on the antidepressant-like activity of desipramine, paroxetine, milnacipran, and bupropion in mice.The influence of caffeine on the activity of moclobemide, venlafaxine, bupropion and milnacipran in the forced swim test in mice.Inhibition of the CRF1 receptor influences the activity of antidepressant drugs in the forced swim test in rats.Traxoprodil, a selective antagonist of the NR2B subunit of the NMDA receptor, potentiates the antidepressant-like effects of certain antidepressant drugs in the forced swim test in mice.Involvement of NMDA receptor complex in the anxiolytic-like effects of chlordiazepoxide in miceChronic treatment with caffeine and its withdrawal modify the antidepressant-like activity of selective serotonin reuptake inhibitors in the forced swim and tail suspension tests in mice. Effects on Comt, Slc6a15 and Adora1 gene expression.Traxoprodil augments the antidepressant-like activity of agomelatine but not of mianserin or tianeptine in the forced swim test in mice.CB1 cannabinoid receptor ligands augment the antidepressant-like activity of biometals (magnesium and zinc) in the behavioural tests.Effects of ifenprodil on the antidepressant-like activity of NMDA ligands in the forced swim test in mice.The effect of an acute and 7-day administration of magnesium chloride on magnesium concentration in the serum, erythrocytes, and brain of rats.The Positive Synergism of CPT and MK-801 in Behavioral Tests and in Reduction of Environmental Stress and Redox Signaling Changes in Mice Cerebral Cortex.8-Cyclopentyl-1,3-dimethylxanthine enhances effectiveness of antidepressant in behavioral tests and modulates redox balance in the cerebral cortex of mice.Cannabinoids in depressive disordersThe influence of selective A1 and A2A receptor antagonists on the antidepressant-like activity of moclobemide, venlafaxine and bupropion in miceDPCPX, a selective adenosine A1 receptor antagonist, enhances the antidepressant-like effects of imipramine, escitalopram, and reboxetine in mice behavioral testsThe influence of nebivolol on the activity of BRL 37344 - the β3-adrenergic receptor agonist, in the animal model of detrusor overactivity.Withdrawal of caffeine after its chronic administration modifies the antidepressant-like activity of atypical antidepressants in mice. Changes in cortical expression of Comt, Slc6a15 and Adora1 genesA Novel Alternative in the Treatment of Detrusor Overactivity? In Vivo Activity of O-1602, the Newly Synthesized Agonist of GPR55 and GPR18 Cannabinoid ReceptorsLigands of the CB2 cannabinoid receptors augment activity of the conventional antidepressant drugs in the behavioural tests in miceThe role of magnesium and zinc in depression: similarities and differencesInfluence of the CB1 and CB2 cannabinoid receptor ligands on the activity of atypical antidepressant drugs in the behavioural tests in miceAntidepressant-Like Activity of Typical Antidepressant Drugs in the Forced Swim Test and Tail Suspension Test in Mice Is Augmented by DMPX, an Adenosine A2A Receptor AntagonistIntravesical administration of blebbistatin prevents cyclophosphamide-induced toxicity of the urinary bladder in female Wistar ratsInfluence of the CB1 cannabinoid receptors on the activity of the monoaminergic system in the behavioural tests in miceAgomelatine and tianeptine antidepressant activity in mice behavioral despair tests is enhanced by DMPX, a selective adenosine A2A receptor antagonist, but not DPCPX, a selective adenosine A1 receptor antagonist
P50
Q34507065-4E8A37AC-B494-47DA-91AF-46120DB1D387Q34655426-04F41E8D-027C-40F8-9E73-2A85CE7B3B35Q36471008-C82DDD43-BA50-4CEE-9A94-D14F54FC82A5Q39026950-621397AC-A6E8-47E3-B435-D5FF75D5385EQ39143939-34C1ECDD-21F6-4193-95A2-2EAE6AA0BD4DQ40775206-0E2801B6-AC10-46B5-AD21-62157E273383Q41010507-BE5D7B85-4680-4A85-8071-9B4D56E4C54FQ42015236-70BDAD45-37A6-40EB-B9C5-FA9036A50E30Q42019741-0C17F46E-EC12-4619-98EB-B6C7C39F8EF3Q47437307-652DD222-D15E-4A81-9D74-4652C42C097AQ48050098-E8B2DFC9-DC09-43E0-B26F-5CB46557DB07Q48144506-2544BE61-5C23-433A-B3A8-302A1239E4FDQ48460815-C0F64D84-670E-4DA3-BB03-EFB977D158E7Q48874192-CE361E3A-FE31-495B-BE43-FFB8D741CB3AQ51769626-024B645E-2FCB-46A4-97DF-9B778F35C003Q55510214-B4C074C1-B28B-49D8-9A84-D98DC6774887Q57048105-628358FE-9785-4E0B-85AA-999C7E4427E7Q57164994-BDF2CDC8-37A3-4229-B049-0673018D8870Q58791740-1C3828F5-56E7-4CD7-93A5-628AA65ECCDCQ67405043-A140473C-41F0-4E62-9793-B88DC3EE3DE3Q89036777-4F456EDD-B6FD-406C-80C2-3719C701E517Q90523014-DFCD8BC2-55E6-4639-8ADA-C46AE0EC9004Q90798831-54058F37-8009-4DB1-B411-3B84A2D9B45CQ91326965-B703D5C4-9D47-4252-9DD1-190C51C0F0DCQ91564454-9D236F33-A48E-44D7-A5E8-2B39375A8963Q91863400-8859FB42-778B-4A9A-8E27-DF5B9B709459Q92354333-EEA5E57D-F812-445F-9E99-7045A505E2C6Q92489596-DE33A6B3-0FA1-40DA-BF1D-E774979491D0Q92754173-EC295078-69EF-452C-98C9-409AB414DE09
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Aleksandra Szopa
@ast
Aleksandra Szopa
@en
Aleksandra Szopa
@es
Aleksandra Szopa
@nl
type
label
Aleksandra Szopa
@ast
Aleksandra Szopa
@en
Aleksandra Szopa
@es
Aleksandra Szopa
@nl
prefLabel
Aleksandra Szopa
@ast
Aleksandra Szopa
@en
Aleksandra Szopa
@es
Aleksandra Szopa
@nl
P214
P106
P1153
49664223700
P214
P31
P4012
P496
0000-0002-7756-2904
P7859
viaf-316012219